Equibles does not estimate personal net worth.
Get an email with a short summary when Cytek Biosciences, Inc. publishes a filing, an earnings call transcript or a press release.
Get CTKB alertsWilliam McCombe is recorded as CFO at Cytek Biosciences, Inc. (CTKB). The newest filing on record that lists William McCombe as CFO at Cytek Biosciences, Inc. (CTKB) is dated April 28, 2026. The proxy statement of Cytek Biosciences, Inc. reports total compensation of $2,460,979 for William McCombe in fiscal 2025, including a base salary of $450,000. Disclosed compensation is on record for 2 fiscal years. William McCombe has spoken on 9 earnings calls across 1 company, most recently for Cytek Biosciences, Inc. on November 4, 2026. Cytek Biosciences, Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Cytek Biosciences, Inc. includes Wenbin Jiang (CEO and Board Member), William ("Bill") McCombe (CFO), Chris Williams (COO) and 6 others.
“Turning to slide 7, third quarter revenue came in at $53.2 million, an increase of 2% compared to Q3 2025. 25. A highlight for the quarter was the strong customer demand for our high-end analyzers with revenue growth of over 30% for the Aurora, Aurora Evo, and Boyalus category.”
“Before I discuss the quarterly and full-year numbers, I want to comment on the macro trends we saw play out across the quarters of 2025. Beginning in the first quarter, macro uncertainties and weak demand resulted in total revenue declining 8% year-on-year.”
“Turning to slide seven in our third quarter financial results, total revenue for Q3 was $52.3 million, a 2% increase versus Q3 of 2024. This reflects strong growth in service and reagents worldwide, in instruments in Asia-Pacific, and stabilization in U.S. instrument revenues.”
“Turning to Slide 9 and our second quarter financial results. Total revenue for Q2 was $45.6 million, a 2% decrease versus Q2 of 2024. This reflects continued weakness in instrument revenue in EMEA and APAC, offset by strong growth in service and growth in U.S. product revenue.”
“Turning to Slide seven and our first quarter financial results. Total revenue for the first quarter of 2025 was $41.5 million, a 7.6% decrease compared to the first quarter of 2024.”
Start not stated–present
Last confirmed April 28, 2026
Medical Devices · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Cytek Biosciences, Inc. (CTKB) | Chief Financial Officer | $450,000 | $2,460,979 |
| 2024 | Cytek Biosciences, Inc. (CTKB) | Chief Financial Officer | $315,000 | $1,689,261 |
